Abstract 4394: GFH375 (VS-7375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models

医学 克拉斯 癌症 药理学 癌症研究 内科学 结直肠癌
作者
Jonathan A. Pachter,Feng Yan,Sílvia Coma,Cristina Caffarra Malvezzi,Xiuting Liu,Emilia Berardelli,Tao Jiang,Siyuan Le,Nathan Sanburn,Fusheng Zhou,Jiong Lan,David G. DeNardo,Chiara Ambrogio,Qiang Lü
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 4394-4394 被引量:11
标识
DOI:10.1158/1538-7445.am2025-4394
摘要

Abstract KRAS G12D is the most prevalent KRAS mutation in human cancers, present in 37%, 12.5%, 8% and 4.9% of pancreatic, colorectal, endometrial and lung cancers, respectively. Currently there are no FDA approved KRAS G12D-selective inhibitors and thus, cancers with KRAS G12D mutations represent a significant unmet medical need. GFH375 (also known as VS-7375) is an orally available KRAS G12D-selective small molecule inhibitor that binds KRAS G12D in the active (ON; GTP-bound) and inactive (OFF; GDP-bound) states. By blocking the activities of the ON and OFF states of KRAS G12D, GFH375 has the potential to inhibit KRAS G12D signaling and tumor growth more completely than compounds that block KRAS G12D only in the OFF state or only in the ON state. Here we show that among a panel of human cancer cell lines, GFH375 potently and selectively inhibited proliferation of tumor cells bearing a KRAS G12D mutation relative to cell lines bearing wild-type KRAS or non-G12D KRAS mutations. Similarly, in a panel of mouse embryonic fibroblasts (MEFs) engineered to express various human KRAS mutation variants, GFH375 selectively inhibited proliferation of KRAS G12D mutant MEFs relative to MEFs expressing other KRAS G12X or Q61X mutations. Furthermore, GFH375 was more potent than other KRAS G12D inhibitors (e.g. RMC-9805, MRTX1133) in reducing the level of RAF1-bound active KRAS G12D-GTP (ON) and inhibiting cell proliferation in MEFs expressing human KRAS G12D. GFH375 also reduced pERK and pCRAF more potently than these other KRAS G12D inhibitors corresponding with greater increase in pro-apoptotic BIM. In vivo, oral administration of GFH375 single agent induced strong tumor regressions in multiple KRAS G12D colorectal and pancreatic cancer tumor models, including xenograft models and a transplanted pancreatic cancer model derived from KPC genetically engineered mice. GFH375 also demonstrated potent anti-tumor activity in an intracranial GP2D tumor model, suggesting potential to use for treatment of brain metastases. Combination of GFH375 with the anti-EGFR antibody cetuximab induced complete responses in all mice in a colorectal cancer xenograft model, and cetuximab also augmented the antitumor efficacy of GFH375 in pancreatic and lung cancer models. Combination with the RAF/MEK clamp avutometinib also enhanced the anti-tumor efficacy of GFH375. Additional combinations with GFH375 are currently being explored. Altogether, GFH375 is a potent and selective orally active inhibitor of KRAS G12D (ON/OFF) and demonstrated promising anti-tumor activity in multiple KRAS G12D tumor models in vivo as single agent and in combination with other anticancer therapies including cetuximab. These results support the ongoing clinical evaluation of GFH375 for treatment of patients with KRAS G12D mutant cancers (NCT06500676). Citation Format: Jonathan A. Pachter, Feng Yan, Silvia Coma, Cristina Caffarra Malvezzi, Xiuting Liu, Emilia Berardelli, Tao Jiang, Siyuan Le, Nathan Sanburn, Fusheng Zhou, Jiong Lan, David G. DeNardo, Chiara Ambrogio, Qiang Lu. GFH375 (VS-7375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4394.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
共享精神的应助被wuwuwu采纳,获得10
刚刚
刚刚
烧灯续昼完成签到 ,获得积分20
刚刚
1秒前
null的应助被peanuts采纳,获得10
1秒前
路遥发布了新的文献求助10
1秒前
1秒前
Lucas的应助被刘晨飞采纳,获得10
2秒前
2秒前
情怀的应助被神仙师姐采纳,获得10
2秒前
3秒前
3秒前
竹桡发布了新的文献求助10
4秒前
4秒前
热爱科研的小海豹完成签到 ,获得积分10
4秒前
4秒前
彩色布条发布了新的文献求助10
4秒前
5秒前
zln完成签到,获得积分10
5秒前
5秒前
soni发布了新的文献求助10
5秒前
5秒前
6秒前
8秒前
爆米花的应助被成就煎饼采纳,获得10
8秒前
wg发布了新的文献求助10
8秒前
CXR发布了新的文献求助10
8秒前
yiwei完成签到,获得积分10
8秒前
8秒前
revo完成签到,获得积分10
9秒前
9秒前
10秒前
叶素绿发布了新的文献求助10
10秒前
10秒前
五五完成签到,获得积分10
10秒前
11秒前
11秒前
wanci的应助被欣慰的冰旋采纳,获得10
11秒前
威武的友绿完成签到,获得积分10
11秒前
蓝天的应助被ucjudgo采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163746
求助须知:如何正确求助?哪些是违规求助? 9557874
关于积分的说明 21742203
捐赠科研通 7754407
什么是DOI,文献DOI怎么找? 3428345
关于科研通互助平台的介绍 2553000
邀请新用户注册赠送积分活动 2472945